Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Sep-Oct;14(5):555-8.

Methotrexate in primary Sjögren's syndrome

F N Skopouli  1 , P Jagiello, N Tsifetaki, H M Moutsopoulos
Affiliations
  • PMID: 8913659

Methotrexate in primary Sjögren's syndrome

F N Skopouli et al. Clin Exp Rheumatol. 1996 Sep-Oct.

Abstract

Objective: To determine the safety and efficacy of methotrexate (MTX) in the treatment of primary Sjögren's syndrome (SS).

Methods: An open, one-year pilot study of MTX (0.2 mg/kg body weight taken weekly) for the treatment of SS was performed. Seventeen patients with primary SS according to EEC criteria were enrolled in the study. Outcome was determined on the basis of clinical and laboratory parameters.

Results: Weekly administration of MTX resulted in improvement of the main subjective symptoms (dry mouth and eyes) as well as in the frequency of parotid gland enlargement, dry cough and purpura. However, no improvement in the objective parameters of dry eyes and dry mouth were observed. Persistent asymptomatic elevation of the hepatic transaminase levels led to a dosage reduction in 7 patients (41%).

Conclusions: Weekly MTX may be an acceptable form of therapy for SS patients. Double-blind trials are needed to substantiate the efficacy of this therapeutic modality.

PubMed Disclaimer

LinkOut - more resources